Evidence map›Paper›PMID 36277458›Full record

ArticleAJOG global reports2021

Magnesium sulfate pharmacokinetics after intramuscular dosing in women with preeclampsia.

Kathleen Brookfield, Hadiza Galadanci, Lihong Du, Larissa Wenning, Idris Mohammed, Maryam Suleiman, Olufemi T Oladapo, Han Witjes, Brendan Carvalho

Open access · goldAbstract read
In one paragraph

Article in AJOG global reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Kathleen BrookfieldDivision of Perinatology, Oregon Health & Science University, Portland, OR (Dr Brookfield).
Hadiza GaladanciDepartment of Obstetrics & Gynaecology, Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria (Dr Galadanci).
Lihong DuAminu Kano Teaching Hospital, Bayero University, Kano, Nigeria (Dr Mohammed); Merck & Co, Inc, Kenilworth, NJ (Drs Du and Wenning).
Larissa WenningAminu Kano Teaching Hospital, Bayero University, Kano, Nigeria (Dr Mohammed); Merck & Co, Inc, Kenilworth, NJ (Drs Du and Wenning).
Idris MohammedDepartment of Obstetrics & Gynaecology, Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria (Dr Galadanci).
Maryam SuleimanDepartment of Obstetrics & Gynaecology, Mohammed Abdullahi Wase Teaching Hospital, Kano, Nigeria (Dr Suleiman).
Olufemi T OladapoDepartment of Sexual and Reproductive Health and Research (SRH) and UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland (Dr Oladapo).
Han WitjesCertara Strategic Consulting, Oss, The Netherlands (Dr Witjes).
Brendan CarvalhoDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA (Dr Carvalho).
Aminu Kano Teaching Hospital · NGMerck & Co., Inc., Rahway, NJ, USA (United States) · USOregon Health & Science University · USStanford University · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCurrent intramuscular magnesium dosing regimens in low and middle-income countries are based on indirect absorption parameters to inform pharmacokinetic and pharmacodynamic response.

objectiveTo determine if therapeutic serum magnesium levels are obtained in women with severe preeclampsia receiving intramuscular administration of magnesium sulfate using the Pritchard regimen and to compare the key pharmacokinetic variables to those previously published. STUDY

designSerum magnesium levels were obtained at multiple time points at baseline and after magnesium sulfate administration from women with severe preeclampsia receiving the standard Pritchard regimen for seizure prophylaxis at Bayero University, Kano, Nigeria. The pharmacokinetic profiles were constructed for the study cohort and the updated pharmacokinetic model was compared with the one that was previously published.

resultsA total of 80 blood samples were collected from 20 women with severe preeclampsia (45 collected before childbirth and 35 collected after childbirth). After 11.5 hours of magnesium sulfate administration, 63% of women in the cohort had serum magnesium levels of ≥2.0 mmol/L. Data from women receiving the Pritchard regimen combined with data from women previously modeled after the receipt of intravenous magnesium sulfate were adequately described using a 2-compartment model with first-order absorption and linear elimination from the central compartment. All structural pharmacokinetic parameters including clearance, central volume of distribution, peripheral volume of distribution, and intercompartment clearance were adjusted for maternal weight, and the clearance was further adjusted for serum creatinine level and antepartum or postpartum status. The simulated pharmacokinetic profiles of the updated pharmacokinetic model and the previously published pharmacokinetic model are similar. In previously published pharmacokinetic modeling, absorption rate constant=0.32 and absolute bioavailability=0.86. In the updated pharmacokinetic model, absorption rate constant=0.45 and absolute bioavailability=0.91.

conclusionThese data support the use of the Pritchard regimen as acceptable to achieve therapeutic serum magnesium levels and support the reported simulation of serum magnesium levels and eclampsia response associated with different intramuscular regimens.

Indexed as

intravenous magnesiumlow- and middle-income countriesmagnesium pharmacodynamicsmagnesium sulfate dosingPritchard regimenseizure prophylaxissevere preeclampsia

Identifiers

PMID36277458
PMCPMC9563381
OpenAlexW3197001836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.